CORTCorcept Therapeutics Incorporated
Price
+50%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality mixed, nothing alarming, demanding price, growth steady, the market undecided.
We are a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. Cortisol plays a significant role in the body’s response to stress and is essential for survival. Cortisol influences metabolism and the immune system and contributes to emotional stability. Cortisol levels follow a diurnal rhythm that is essential to health, peaking upon awakening and decreasing during the day.
In the company’s own words · 10-K filed Feb 24, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Corcept Therapeutics Incorporated (CORT) reported revenue of $256M in Q2 2026 (quarter ended Jun 30, 2026), up 32% from the same quarter a year earlier. That came with a gross margin of 98% and net income of $43M (17% of revenue). For the full year FY2025, revenue was $761M (+13% year on year) and net income $100M. The next results filing is expected around Nov 3, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 23, 2026On September 22, 2026, Sean Maduck, the President of Corcept Endocrinology, notified the Board of Directors of Corcept Therapeutics Incorporated (the “Company”) of his decision to resign effective as of October 1, 2026.Director or officer change · Form 8-K
- Jul 29, 2026Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update.Earnings release · press release
- Jun 17, 2026On June 17, 2026, Corcept Therapeutics Incorporated (the “Company”) issued a press release announcing that the Company has resubmitted its New Drug Application to the U.S. Food and Drug Administration for relacorilant as a treatment for patients with Cushing’s syndrome.Other event · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.